- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Veracyte Price Target Lowered to $45 by Guggenheim
Analysts cite concerns about the biotechnology company's stock performance
Mar. 30, 2026 at 3:38pm
Got story updates? Submit your updates here. ›
An extreme close-up of the inner workings of the financial system reflects the volatility and uncertainty surrounding Veracyte's stock performance.South San Francisco TodayGuggenheim, an equity research firm, has lowered its price target for Veracyte (NASDAQ:VCYT) from $50 to $45, while maintaining a 'buy' rating on the stock. The analysts cited the biotechnology company's recent stock performance as the reason for the price target reduction.
Why it matters
Veracyte is a leading provider of genomic diagnostics, with its flagship product being the Afirma Genomic Sequencing Classifier, which helps clinicians distinguish benign from suspicious thyroid nodules. The company's stock performance and analyst ratings can impact investor sentiment and the overall perception of the company's growth prospects.
The details
In a research note issued on Monday, Guggenheim analysts lowered their price target on Veracyte from $50 to $45, while reiterating a 'buy' rating on the stock. The new price target still represents a potential upside of 48.56% from the stock's current trading price. The analysts cited the company's recent stock performance as the reason for the price target reduction.
- Guggenheim issued the research note on Monday, March 30, 2026.
The players
Veracyte
A biotechnology company that develops and commercializes minimally invasive genomic tests to aid in the diagnosis of various diseases, including thyroid, lung, and other conditions.
Guggenheim
An equity research firm that provides investment research and analysis on various companies and industries.
What’s next
Investors will be closely monitoring Veracyte's stock performance and any further updates from analysts regarding the company's outlook and growth prospects.
The takeaway
The price target reduction by Guggenheim highlights the volatility and uncertainty surrounding Veracyte's stock, despite the company's leading position in the genomic diagnostics market. Investors will need to carefully evaluate the company's fundamentals and growth potential to make informed investment decisions.
